Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment1.61%-0.81 ppPharmaceuticals4.07%+0.65 ppBiotechnology1.99%+0.19 ppHealth Care Technology0.10%+0.08 ppHealth Care Facilities0.15%-0.04 ppHealth Care Services0.43%-0.04 ppLife Sciences Tools & Services0.93%-0.03 ppManaged Health Care0.85%+0.02 ppHealth Care Supplies0.08%-0.00 ppHealth Care Distributors0.38%-0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.99%
Industry change · 12M
+0.19 pp
Biotechnology · contribution
+0.189 pp
Company participation
100%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Aug 2026 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $56.0bn | 0.093% | +0.061 pp | +0.074 pp | +482.6% | Yes |
| Amgen → AMGN | United States | $232.4bn | 0.387% | +0.072 pp | +0.066 pp | +53.6% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $138.0bn | 0.230% | +0.033 pp | +0.022 pp | +39.3% | Yes |
| AbbVie → ABBV | United States | $453.1bn | 0.755% | +0.088 pp | -0.016 pp | +25.7% | Yes |
| Biogen → BIIB | United States | $32.0bn | 0.053% | +0.003 pp | +0.013 pp | +63.9% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $75.1bn | 0.125% | +0.025 pp | +0.012 pp | +38.3% | Yes |
| Gilead Sciences → GILD | United States | $181.5bn | 0.302% | +0.013 pp | +0.012 pp | +32.9% | Yes |
| Incyte → INCY | United States | $24.6bn | 0.041% | +0.008 pp | +0.007 pp | +45.6% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.